SunStar
(File) May 07, 2021 THE Department of Health (DOH) on Friday, May 7, 2021, announced the resumption of vaccinations using the Oxford AstraZeneca vaccine ahead of the expected delivery of two million doses within the month.
The agency said guidelines on the management of adverse events following immunization (AEFI), particularly for the very rare vaccine-induced thrombosis and thrombocytopenia (VITT), have been updated.
VITT is a very rare condition of blood clots associated with low platelet counts that can occur 4 to 28 days after receiving a viral vector vaccine such as AstraZeneca, DOH said in a statement Friday.
Vaccinations using the AstraZeneca vaccine were halted for individuals below 60 years old on April 8 because of recent reports of very rare cases of blood clots.
Published May 7, 2021, 1:42 PM
The Department of Health (DOH) announced on Friday, May 7, the official resumption of using the AstraZeneca coronavirus disease (COVID-19) vaccine in the country. This file photo taken on November 23, 2020 shows an illustration picture of a syringe and a bottle reading “Covid-19 Vaccine” next to AstraZeneca company and University of Oxford logos. (AFP/ MANILA BULLETIN)
Last April 8, the DOH and the Food and Drug Administration (FDA) temporarily suspended the use of AstraZeneca vaccines for individuals below 60 years old, following reports of rare cases of Vaccine-Induced Thrombosis and Thrombocytopenia (VITT) in some countries.
“After discussions with the DOH All Experts Group and the Philippine College of Hematology and Transfusion Medicine (PCHTM), it was concluded that there are currently no known risk factors for VITT and that the benefits of receiving the vaccine against COVID-19 still outweighs the risk. However, specific guidelines and
By JULIA MARI ORNEDO, GMA News
Published May 7, 2021 2:25pm The Department of Health (DOH) on Friday said guidelines for the management of COVID-19 vaccine side effects have been updated as it announced the official resumption of AstraZeneca vaccination for people younger than 60. The DOH approved earlier this month the recommendation to resume the use of the AstraZeneca jab on people under 60 after it was suspended due to concerns on possible blood clotting with low platelet count. The condition, called vaccine-induced thrombosis and thrombocytopenia (VITT), is a “very rare condition” that can occur four to 28 days after getting a viral vector vaccine like AstraZeneca, the DOH explained.
DOH resumes use of AstraZeneca vaccines for all age groups
THE DEPARTMENT of Health (DOH) has reallowed the use of the Oxford AstraZeneca vaccine for all age groups.
In a statement on Friday, the DOH said based on the recommendation of the Food and Drug Administration (FDA) and the DOH All Experts Group on Vaccines (DOH-AEGV), it was concluded that there are currently “no known risk factors” for vaccine-induced thrombosis and thrombocytopenia (VITT) a very rare condition of blood clots associated with low platelet counts that occur four to 28 days after receiving a viral vector vaccine such as AstraZeneca.
It noted that the benefits of receiving the vaccine “still outweigh the risk”.
DOH 7: Dose 2 of AZ arriving in time for interval due sunstar.com.ph - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sunstar.com.ph Daily Mail and Mail on Sunday newspapers.